The new major version with a new JIT compiler, a revised parallelization API, and a maturing type system paves the way for ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

Open WebUI, an open-source, self-hosted web interface for interacting with local or remote AI language models, carried a high ...